KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Other financing activities (2017 - 2025)

Aquestive Therapeutics has reported Other financing activities over the past 7 years, most recently at $7000.0 for Q3 2025.

  • Quarterly results put Other financing activities at $7000.0 for Q3 2025, down 12.5% from a year ago — trailing twelve months through Sep 2025 was $3000.0 (up 100.04% YoY), and the annual figure for FY2023 was $4.6 million, changed.
  • Other financing activities for Q3 2025 was $7000.0 at Aquestive Therapeutics, down from $8000.0 in the prior quarter.
  • Over the last five years, Other financing activities for AQST hit a ceiling of $9.1 million in Q1 2023 and a floor of -$7.9 million in Q4 2023.
  • Median Other financing activities over the past 3 years was $6000.0 (2025), compared with a mean of $424000.0.
  • Peak annual rise in Other financing activities hit 99.77% in 2024, while the deepest fall reached 99.94% in 2024.
  • Aquestive Therapeutics' Other financing activities stood at -$7.9 million in 2023, then skyrocketed by 99.77% to -$18000.0 in 2024, then surged by 138.89% to $7000.0 in 2025.
  • The last three reported values for Other financing activities were $7000.0 (Q3 2025), $8000.0 (Q2 2025), and $6000.0 (Q1 2025) per Business Quant data.